Kid’s Medication for Psoriasis, Arthritis Linked to Cancer
The FDA warns that TNF blockers -- the immune-disease drugs Remicade, Enbrel, Humira, Cimzia, and Simponi -- may cause lymphoma and other cancers in children and teens.
The drugs already carry a black-box warning that they may cause cancer. But the FDA now says the warning labels must highlight the drugs' possible risk of lymphoma and other cancers in children and teens.
TNF blockers neutralize a protein, tumor necrosis factor alpha, that is overproduced in inflammatory diseases. The drugs are used to treat juvenile rheumatoid arthritis, juvenile idiopathic arthritis (JIA), psoriatic arthritis, psoriasis, Crohn's disease, ankylosing spondylitis, and other autoimmune diseases.
TNF, however, has a normal function in the body: fighting cancer.
In a June 2008 alert, the FDA announced that it was investigating the link between TNF blockers and cancer in children and teens. That investigation, now complete, identified 48 cases of malignant cancers in children and teens and 147 cases of leukemia in all patients (including adults) taking TNF blockers.
The agency warns doctors and patients to be aware of the risk and to be on the lookout for any early signs of cancer.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
